April 17, 2024


Health is important

Diamyd Medical secures precision medicine patent for prevention and treatment of autoimmune diabetes

STOCKHOLM, Sweden, Aug. 9, 2021 /PRNewswire/ — The European Patent Place of work has informed Diamyd Professional medical that the Firm’s patent software with regards to prevention and treatment method of autoimmune diabetic issues in individuals carrying the HLA DR3-DQ2 gene will be granted. The patent is valid until finally 2035 and supplies central protection in Europe for the therapy or prevention of genetically outlined autoimumune diabetes using GAD, which is the energetic element in the therapeutic diabetes vaccine Diamyd®. The patent promises protect the affected individual population in which Diamyd® has revealed efficacy and is specific in the upcoming Phase III trial DIAGNODE-3.

“The granted patent is a substantial milestone for Diamyd Medical and our concentration on precision drugs for autoimmune diabetic issues”, states Ulf Hannelius, CEO of Diamyd Medical. “The time is ripe for protected and targeted therapeutic diabetes vaccines, therapies that may perhaps revolutionize our options to eliminate this devastating condition.”

HLA DR3-DQ2 has been proven to be related with autoimmunity in opposition to GAD and represents one of the most popular genetic possibility elements for form 1 diabetic issues since about 40% of individuals with kind 1 diabetes carry  the gene. A big-scale meta-assessment released in Diabetologia in 2020 confirmed that positivity for HLA DR3-DQ2 is associated with medical reaction to the diabetic issues vaccine Diamyd®. This was prospectively confirmed in the Stage IIb demo DIAGNODE-2 that was released in Diabetes Care in May well 2021.

In addition to the precision medication patent that will be granted in Europe, Diamyd Health-related by now holds, as component of an exclusive license from the University of California, Los Angeles (UCLA), patent safety in the United States, which is valid until 2032 for the procedure of diabetic issues with GAD, a major autoantigen in autoimmune diabetic issues. Diamyd Healthcare also holds patent protection valid until finally 2035 in Europe, Japan, Russia, Israel and Australia for intralymphatic administration of Diamyd®, the administration route used in the DIAGNODE-1 and -2 medical trials and to be utilized in the forthcoming Phase-3 demo with Diamyd®.

As a biological drug, Diamyd® will, independently of patent security, love twelve and 10 a long time market exclusivity from the date of current market acceptance in the US and Europe respectively.

About Diamyd Health care
Diamyd Medical develops precision drugs therapies for kind 1 diabetes. The diabetic issues vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin output. Significant effects have been shown in a large genetically predefined client group in a substantial-scale meta-examination as effectively as in the Firm’s European Period IIb trial DIAGNODE-2, wherever the diabetic issues vaccine was administered instantly into a lymph node in youngsters and youthful adults with just lately identified sort 1 diabetic issues. Preparations for a confirmatory Period III demo in the US and Europe are on-likely, to commence recruting individuals later on in 2021. A vaccine production facility is being established up in Umeå for the manufacture of recombinant GAD65, the lively component in the therapeutic diabetic issues vaccine Diamyd®. Diamyd Health care also develops the GABA-based investigational drug Remygen® as a treatment for regeneration of endogenous insulin creation and to improve hormonal reaction to hypoglycaemia. An investigator-initiated Remygen® trial in people living with style 1 diabetic issues for much more than 5 many years is ongoing at Uppsala College Medical center. Diamyd Professional medical is a single of the major shareholders in the stem mobile company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq To start with North Advancement Industry beneath the ticker DMYD B. FNCA Sweden AB is the Firm’s Qualified Adviser cellular phone: +46 8-528 00 399, e-mail: [email protected].

Speak to:

For further details, be sure to make contact with:
Ulf Hannelius, President and CEO
Cellphone: +46 736 35 42 41
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://information.cision.com/diamyd-professional medical-ab/r/diamyd-health-related-secures-precision-medication-patent-for-prevention-and-therapy-of-autoimmune-diabetes,c3393510

The next files are accessible for obtain:

Source Diamyd Health-related AB